Can Orexigen Therapeutics Catch Up With Arena Pharmaceuticals and VIVUS?
Orexigen Therapeutics hopes that its Contrave obesity drug will gain approval, but VIVUS' Qsymia and Arena Pharmaceuticals' Belviq already have a head start.
Can Arena's Obesity Handoff Create a Touchdown?
Arena Pharmaceuticals expands its marketing partnership with Eisai. The Japanese pharma's endorsement could be a good sign that VIVUS and Orexigen are on the right track.
Why Arena Pharmaceuticals, Santarus, and Universal Display Soared Today
The stock market soared on a strong employment report, but even the Dow's 168-point gain paled in comparison to a 17% jump for Arena Pharmaceuticals, a 38% rise for Santarus, and a 26% advance for Universal Display. Find out more about what helped these stocks soar.
Key Takeaways From Vivus' Bad Quarter
Here's why the market gutted Vivus after its earnings report.